Paula R Pohlmann

25PUBLICATIONS
173CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Sep 22, 2026
Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.

|Aug 27, 2026
Neoadjuvant Palbociclib Treatment Impacts Cell Cycle Progression of DCIS.

|Dec 09, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.

Mark Jesus M Magbanua, Nayelis A Manon, Denise M Wolf

|Nov 24, 2025
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.

Taiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav

|Aug 27, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit.

Camila Braganca Xavier, Clark R Andersen, JoAnn Lim

|Jun 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

Denise M Wolf, Christina Yau, Michael Campbell

Pageof 5

Frequent Collaborators

7 joint publications

Gillian L Hirst

6 joint publications

Laura van 't Veer

6 joint publications

Claudine Isaacs

6 joint publications

Lamorna Brown-Swigart